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Abstract
Background: Previous work showed that daily ingestion of an aqueous soy extract fermented with Enterococcus
faecium CRL 183 and Lactobacillus helveticus 416, supplemented or not with isoflavones, reduced the total
cholesterol and non-HDL-cholesterol levels, increased the high-density lipoprotein (HDL) concentration and
inhibited the raising of autoantibody against oxidized low-density lipoprotein (ox-LDL Ab) and the development of
atherosclerotic lesions.
Objective: The aim of this study was to characterize the fecal microbiota in order to investigate the possible
correlation between fecal microbiota, serum lipid parameters and atherosclerotic lesion development in rabbits
with induced hypercholesterolemia, that ingested the aqueous soy extract fermented with Enterococcus faecium
CRL 183 and Lactobacillus helveticus 416.
Methods: The rabbits were randomly allocated to five experimental groups (n = 6): control (C),
hypercholesterolemic (H), hypercholesterolemic plus unfermented soy product (HUF), hypercholesterolemic plus
fermented soy product (HF) and hypercholesterolemic plus isoflavone-supplemented fermented soy product (HIF).
Lipid parameters and microbiota composition were analyzed on days 0 and 60 of the treatment and the
atherosclerotic lesions were quantified at the end of the experiment. The fecal microbiota was characterized by
enumerating the Lactobacillus spp., Bifidobacterium spp., Enterococcus spp., Enterobacteria and Clostridium spp.
populations.
Results: After 60 days of the experiment, intake of the probiotic soy product was correlated with significant
increases (P < 0.05) on Lactobacillus spp., Bifidobacterium spp. and Enterococcus spp. and a decrease in the
Enterobacteria population. A strong correlation was observed between microbiota composition and lipid profile.
Populations of Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. were negatively correlated with total
cholesterol, non-HDL-cholesterol, autoantibodies against oxidized LDL (oxLDL Ab) and lesion size. HDL-C levels
were positively correlated with Lactobacillus spp., Bifidobacterium spp., and Enterococcus spp. populations.
Conclusion: In conclusion, daily ingestion of the probiotic soy product, supplemented or not with isoflavones, may
contribute to a beneficial balance of the fecal microbiota and this modulation is associated with an improved
cholesterol profile and inhibition of atherosclerotic lesion development.
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The human intestinal microbiota plays an important role
in maintaining human health, preventing colonization by
pathogenic microorganisms, breaking down dietary com-
pounds, producing nutrients and keeping the intestinal
mucosa in a healthy state. Other important functions
have begun to be unveiled over the past few years, sug-
gesting that the effects of the gut microbiota may be
more profound, influencing complex processes such as
glucose and lipid metabolism, predisposition to obesity
and disorders mediated by the immune system, including
inflammatory bowel disease, autoimmune conditions and
allergic reactions [1,2].
Cardiovascular diseases (CVD) are the main cause of
death around the world and dyslipidemia is a key factor
in susceptibility to coronary heart disease (CHD) and
other atherosclerotic diseases [3].
Recent research has afforded strong evidence suggesting
that the gut microbiota could influence host cholesterol
metabolism [4]. The mechanisms involved in this effect
include modifications of bile acids that affect enterohepatic
circulation, de novo synthesis of bile acids and cholesterol
absorption and inhibition of lipoprotein lipase [5,6].
In previous studies, we have shown that daily ingestion
of an aqueous soy extract fermented with Enterococcus
faecium CRL 183 and Lactobacillus helveticus 416, sup-
plemented or not with isoflavones, could improve the
lipid profile in animal and human tests [7-10]. Using
New Zealand rabbits, Cavallini et al. (2009) [11] demon-
strated that the same probiotic product, with or without
isoflavones, leads to a significant reduction of serum total
cholesterol and non-high density lipoprotein-cholesterol
(non-HDL-C), increases the high-density lipoprotein
(HDL) level, inhibition of the raise of autoantibody
against oxidized low-density lipoprotein (ox-LDL Ab)
and slows the development of atherosclerotic lesions. In
this study, we intend to characterize the fecal microbiota
of rabbits that ingest the aqueous soy extract fermented
with Enterococcus faecium CRL 183 and Lactobacillus
helveticus 416, in order to investigate the possible corre-
lation of specific modification of fecal microbiota, serum
lipid parameters and atherosclerosis development.
Material and Methods
Animals and experimental protocol
Male New Zealand white rabbits (n = 30, 8-9 weeks old,
weighing 2.5-3.0 Kg; obtained from Central Animal Facil-
ity of Sao Paulo State University, Botucatu, SP, Brazil)
were housed in individual cages in temperature-controlled
rooms (22°C ± 2°C), with a light-dark cycle of 12:12 h.
Rabbits were fed a chow diet (Purina, SP, Brazil) for
1 week to acclimatize the animals and then randomly
allocated to five experimental groups (n = 6): control
(C), hypercholesterolemic (H), hypercholesterolemic
plus unfermented soy product (HUF), hypercholesterole-
mic plus fermented soy product (HF) and hypercholes-
terolemic plus isoflavone-supplemented fermented soy
product (HIF).
The control group (C) was fed only on commercial
rabbit food (Nutri Rabbit Special Chow Purina; nutri-
tional make-up per 100 g: 23 g protein, 4 g fats, 49 g
carbohydrates, 5 g fiber and 10 g minerals). The other
g r o u p s( H ,H U F ,H Fa n dH I F )w e r ef e do nt h es a m e
rabbit diet, to which cholesterol (Sigma C 8503) had
been added to induce hypercholesterolemia. The level
of cholesterol added to the diet was adjusted during
the experiment (1.0% down to 0.7% after 30 days), to
maintain the animal healthy and the feed was prepared
as previously described (Cavallini et al., 2009). The
rabbits received restrict amounts (125 g/d) of each diet
and had free access to water during the experimental
period.
The fermented soy product was processed at the Devel-
opment and Production Unit for Soybean Derivatives
(UNISOJA, Food and Nutrition Department of the School
of Pharmaceutical Sciences, UNESP at Araraquara - SP,
Brazil), using the method described by Rossi et al (1989).
The bacterial inoculum consisted of 3% (v/v) of a 1:1
mixture of Enterococcus faecium CRL 183 (probiotic
microorganism, from Centro de Referencia para Lactobaci-
los - CERELA - Argentina) and Lactobacillus helveticus
416 (fermentation adjuvant, from Institute of Food
Technology - ITAL - Campinas, Brazil). Isoflavone-suple-
mented fermented soy product was prepared by adding
Isoflavin
® (Galena, Brazil), before the fermentation, at
75 mg (total isoflavone) per 100 g. Fermented soy product,
supplemented or not with isoflavones, exhibited cell viable
counts between 10
9 -1 0
10 CFU/mL. Unfermented soy
product was prepared by chemical acidification of soy pro-
duct basic mixture (without bacterial culture or isofla-
vone), to reach the same pH as the fermented soy product
(4.4 - 4.6), by adding food-grade lactic acid (Synth, Sao
Paulo, SP, Brazil). The chemical composition of the pro-
ducts is presented in Table 1.
Groups HUF, HF and HIF received, by gavage once a
day, unfermented soy product (2.8 mL/kg body weight),
fermented soy product (2.8 mL/kg body weight) and iso-
flavone-supplemented fermented soy product (2.8 mL/kg
body weight - 2.1 mg of total isoflavone/kg body
weight), respectively.
The experiment was carried out for 60 days. The fecal
microbiota, lipid parameters and atherosclerotic lesion
development were analyzed before the start (T0) and at
the end of the experimental period (T60).
The experimental design received approval (n° 03/2007)
from the Research Ethics Committee of the School of
Pharmaceutical Sciences, UNESP at Araraquara (SP,
Brazil).
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Stools were collected from the cages for 24 hours at the
each sampling time (days 0 and 60). Samples were col-
lected in aseptic plastic bags, placed in anaerobic jars with
gas-generating kits (Anaerobac, Probac, Brazil) and then
analyzed for bacterial counts as soon as possible, as
described below.
Blood Sampling
Blood was drawn from the marginal ear vein, after a 14 to
16-hour fast. The samples were centrifuged (3500 x g for
10 min) and the serum taken for lipid profile determina-
tion. For the oxLDL Ab determination, plasma was first
separated from the blood by centrifugation (3500 × g for
10 min at 4°C), then 1.0 mmol/L phenylmethylsulfonyl
fluoride (Sigma Chemical), 2.0 mmol/L benzamidine
(Sigma Chemical), 2.0 mg/L aprotinin (Sigma Chemical)
and 20.0 mmol/L BHT (Sigma Chemical) were added to
the samples of plasma.
Analysis of Serum lipids
The serum levels of total cholesterol (TC), high-density
lipoprotein (HDL-C) and triglycerides were assayed in
each rabbit, with the aid of specific enzyme kits. TC
was measured by the cholesterol fast color method
[12]. HDL-C was estimated by first selectively precipi-
tating lipoproteins [13] and then applying the TC
method to the supernatant. Non-HDL cholesterol was
calculated by subtracting HDL-C from TC and was
composed of the LDL+IDL+VLDL cholesterol fractions
[14,15].
Detection of autoantibodies against oxidized LDL
(oxLDL Abs)
The autoantibodies against oxLDL were assayed in
plasma by ELISA, as previously described [16,17]. The
data were presented as milli Arbitrary Units (mAU/L).
Analysis of atherosclerotic lesions
After the 60 days of the experiment, the rabbits were
heparinized and euthanized by an overdose of sodium phe-
nobarbital (130 mg/kg body weight - Cristália, SP, Brazil)
and the aorta was removed to analyze the macroscopic
atherosclerotic lesions. The aorta was divided into the
following segments: 1) aortic arch; 2) thoracic and abdom-
inal aortas. The material was fixed overnight, at room tem-
perature, in 10% buffered formaldehyde solution and
stained with Sudan IV to reveal areas of atherosclerotic pla-
que [18]. The stained aorta was photographed with a digital
camera (Sony) and the sudanophilic lesions were identified
and quantified. The surface area of the atherosclerotic
lesions was measured with an image analyzer system (Ima-
gelab - USP - Brazil) and expressed as a percentage of the
total aortic surface area covered by lesion.
Analysis of fecal microbiota
Each fecal sample (1 g) was homogenized in a stomacher,
with sterile peptone water (99 g). Subsequent tenfold serial
dilutions were plated in triplicate on the following selec-
tive media to distinguish bacterial genera: Enterococcus
spp.: KF Streptococcus agar (Acumedia) [19]; Lactobacillus
spp.: MRS agar (Merck, Darmstadt, Deutschland, Ger-
many) [20]; Bifidobacterium spp.: Bifidobacterium iodoa-
cetate medium 25 (BIM-25) [21]; Enterobacteria:
MacConkey agar (Acumedia) [22]; Clostridium spp.: RCA
agar (Difco, Le Point de Claix, France) [23]. Plates for
Enterococcus spp. and Enterobacteria were incubated at
37°C for 48 h. Plates for Lactobacillus spp., Clostridium
spp. and Bifidobacterium spp were incubated anaerobi-
cally, in anaerobic jars with gas-generating kits, at 37°C for
48 h, 48 h and 72 h, respectively.
Statistical analysis
Results are presented as means ± standard deviations.
One-way ANOVA was used to determine a significant
Table 1 Composition of unfermented soy product, fermented soy product and isoflavone-supplemented fermented
soy product
Composition Unfermented Soy Product Fermented Soy Product Isoflavone-Supplemented Soy Product
Protein (g/100 g) 3.85 ± 0.04 3.90 ± 0.00 3.85 ± 0.00
Fat (g/100 g) 2.32 ± 0.02 2.30 ± 0.08 2.26 ± 0.09
Carbohydrate (g/100 g) 9.93 ± 0.16 9.70 ± 0.15 10.06 ± 0.11
Ash (g/100 g) 0.90 ± 0.00 0.90 ± 0.07 0.90 ± 0.00
Moisture(g/100 g) 83.00 ± 0.16 83.20 ± 0.00 82.93 ± 0.17
Total isoflavone (mg/100 g) 8.03 ± 0.07 8.04 ± 0.01 51.26 ± 1.12
Daidzin (mg/100 g) 2.00 ± 0.03 2.09 ± 0.04 4.68 ± 0.27
Genistin (mg/100 g) 5.76 ± 0.05 5.69 ± 0.04 6.72 ± 0.02
Daidzein (mg/100 g) 0.26 ± 0.01 0.26 ± 0.01 32.62 ± 0.94
Genistein (mg/100 g) - - 7.25 ± 0.22
Final pH 4.6 4.45 4.55
Values represent mean ± SEM (n = 3). Fermented soy product and isoflavone-supplemented soy product were fermented by a mixed culture of Enterococcus
faecium CRL 183 and Lactobacillus helveticus 416.
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used to perform multiple comparisons between means.
The difference between study periods was verified by
Student’s t-test. Correlations between cardiovascular risk
factors and bacterial populations were assessed by Pear-
son’s correlation test.
Results
Lipid parameters and atherosclerotic lesion
The effects of treatments on lipid parameters are shown
in Table 2.
After 60 days of treatment, rabbits that received fermen-
ted soy product exhibited the greatest reduction (p < 0.05)
in n-HDL-C (38.7%), relative to group H. Animal in the
groups HF, HIF and HUF exhibited significantly lower TC
levels than group H (38.1%, 27.0% and 26.6% respectively).
The HDL-C level was higher in animals that received
the fermented soy product, supplemented or not with
isoflavones (55.2%), and unfermented soy product
(35.8%), than in group H. However, statistical compari-
son of samples at different times showed that only the
HF and C groups showed no reduction in HDL-C levels
after 60 days of the experiment.
The animals fed a high cholesterol diet (H) and unfer-
mented soy product (HUF) exhibited a rapid rise in anti-
oxLDL Ab (P < 0.05), while the fermented soy product
(HF) and fermented soy product supplemented with isofla-
vones (HIF) reduced the rise in this parameter during the
experiment.
Comparisons of atherosclerotic lesion area in aortic seg-
ments are shown in Figure 1. The extent of atherosclerosis
on the whole aorta demonstrated that animals treated
with fermented soy product supplemented with isofla-
vones exhibited the lower percentage of aortic area cov-
ered with lesion (19,0%), differing significantly from the
group H (39,13%).
Characterization of fecal microbiota
The fecal bacterial counts of the different treatment
groups are summarized in Table 3. At the start of the
protocol the microbiota compositions of the rabbits
groups were different (p < 0.05), so that the comparison
of times was more relevant.
After 60 days of treatment, animals that consumed only
the hypercholesterolemic diet (group H) showed a signifi-
cant reduction in all bacteria groups studied, including the
beneficial genera Bifidobacterium spp. and Lactobacillus
spp. Rabbits fed a probiotic soy product (HF) and com-
mercial chow (C) showed a significant increase in Bifido-
bacterium spp. counts. The population of Lactobacillus
spp. was increased in the animals that received fermented
soy product, supplemented or not with isoflavones, and in
the control group. Unfermented soy product was unable
to increase or prevent the decrease of Bifidobacterium spp.
and Lactobacillus spp. populations.
Fecal Enterococcus spp. population was significantly
increased in the groups control (C), hypercholesterolemic
plus unfermented soy product (HUF), hypercholesterole-
mic plus fermented soy product (HF) and hypercholester-
olemic plus isoflavone-suplemented fermented soy
product (HIF). All the treatment groups displayed a
decrease in the Enterobacteria counts during the experi-
ment. By the end of the study, the population of Clostri-
dium spp. fell significantly in all groups, excepting in the
animals of the hypercholesterolemic plus fermented soy
product group (HF), compared to basal period (T0).
Correlation of fecal microbiota and metabolic parameters
The analysis showed a strong negative correlation
between serum concentrations of total cholesterol, non-
HDL-C and autoantibody against oxidized LDL and area
of atherosclerotic lesion, on one hand, and Enterococcus
spp., Lactobacillus spp. and Bifidobacterium spp. counts,
Table 2 Serum lipids and oxLDL Abs among the groups
Serum lipids Time C H HUF HF HIF
TC
(mg/dL) T0 49.0 ± 3.7
aA 42.0 ± 2.8
aB 44.8 ± 5.8
aB 45.3 ± 5.1
aB 44.5 ± 5.4
aB
T60 53.3 ± 6.2
bA 2556.5 ± 120.3
aA 1876.3 ± 233.6
bA 1583.8 ± 86.3
cA 1867.5 ± 251.7
bA
HDL-C
(mg/dL) T0 31.5 ± 2.3
aA 28.5 ± 2.5
aA 31.50 ± 3.6
aA 32.0 ± 2.6
aA 31.8 ± 1.1
aA
T60 26.8 ± 2.8
aA 16.8 ± 2.8
cB 22.8 ± 2.8
abB 32.0 ± 2.6
aA 26.0 ± 2.1
aB
n-HDL-C
(mg/dL) T0 17.5 ± 2.6
aB 13.5 ± 2.9
aB 13.3 ± 2.4
aB 13.3 ± 3.0
aB 12.3 ± 2.3
aB
T60 26.5 ± 4.4
cA 2539.8 ± 120.2
aA 1853.5 ± 231.8
bA 1557.8 ± 86.6
bA 1841.5 ± 249.8
bA
oxLDL Abs
(mAU/L) T0 0.204 ± 0.104
aA 0.339 ± 0.129
aB 0.323 ± 0.105
aB 0.390 ± 0.289
aA 0.338 ± 0.166
aA
T60 0.316 ± 0.156
bA 1.809 ± 0.514
aA 0.799 ± 0.285
bA 0.553 ± 0.296
bA 0.530 ± 0.232
bA
Values (in mg/dL) represent mean ± SEM (n = 6). C = control; H = hypercholesterolemic; HUF = hypercholesterolemic plus unfermented soy product, HF =
hypercholesterolemic plus fermented soy product, HIF = hypercholesterolemic plus isoflavone-supplemented fermented soy product. T0 = before the start of the
study, T60 = end of the experiment. Statistical comparison of treatment groups: means with identical lower-case letters in the same row do not differ
significantly (P ≤ 0.05). Statistical comparison of times: means with identical upper-case letters in the same column do not differ significantly (P ≤ 0.05).
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and these microorganisms genera (Table 4). The Entero-
bacteria population was negatively correlated only with
the HDL-C. Finally the levels of autoantibody against
oxidized LDL and the size of atherosclerotic lesion were
negatively correlated with the Clostridium spp. count.
For the most of analyzed parameters, the correlations
were observed only when the values of control group
(without induced hypercholesterolemia) were not
considered.
Discussion
Daily ingestion of aqueous soye x t r a c tf e r m e n t e dw i t h
Enterococcus faecium CRL 183 and Lactobacillus helve-
ticcus 416, supplemented or not with isoflavones, was
found to reduce the risk of cardiovascular disease by
improving the lipid profile and inhibiting oxLDL Ab for-
mation. Earlier studies have shown the hypolipemiant
and anti - atherogenic properties of this product in var-
ious animal models and clinical trials [8-11].
In the colon, the microbiota is comprised mainly of
anaerobes such as Bacteroides spp., Porphyromonas spp.,
Bifidobacterium spp., Lactobacillus spp. and Clostridium
spp. The composition of human microbiota remains rela-
tively constant throughout the adult life, but it may be
influenced by age, diet and socio-economic conditions
and, mainly, by the use of antibiotics [24,25].
Some bacterial genera in the gut, such as Bifidobacter-
ium spp. and Lactobacillus spp., are considered beneficial
to the host, while others can be potentially pathogenic
[26,27]. In this context, there is a consensus among
researchers that several human disease states have bene-
fited from the use of probiotics, most notably, diarrhea,
some inflammatory bowel diseases, infectious disorders,
irritable bowel syndrome and dyslipidemia [25].
After 60 days of the experiment, intake of probiotic soy
product was related to significant increases (P < 0.05) in
Lactobacillus spp. and Bifidobacterium spp. counts indi-
cating that the presence of the probiotic microorganisms
(E. faecium CRL183 and L. helveticus 416) stimulated the
growth of beneficial microorganisms (Lactobacillus spp.
and Bifidobacterium spp.), since the unfermented pro-
duct was not able to increase the populations of these
fecal bacteria genera. Similar results were observed by
other researchers, when rats on a beef-based diet were
treated with the same fermented product, without isofla-
vone supplementation [26].
The increase in the population of intestinal bifidobac-
teria represents a beneficial effect for the host, since
these microorganisms are involved in the production of
short chain fatty acids (SCFA), reduction of intestinal
pH, reduction of putrefaction products, inhibition of the
growth of pathogens and immunomodulation [28].
The population of Enterococcus spp. decreased only in
the hypercholesterolemic group (H). However, it is
important to emphasize that the animals under treatment
with the probiotic product (HF and HIF) exhibited the
largest increases in number of microrganisms of this
genus, demonstrating the probable persistence in the gut
of the probiotic E. faecium strain during the feeding per-








































Figure 1 Percentage of aortic area of whole aorta (thoracic and
arch) covered with lesion. The bar graphs represent the average
(n = 6) for each group with standard errors. C = control; H =
hypercholesterolemic; HUF = hypercholesterolemic plus
unfermented soy product, HF = hypercholesterolemic plus
fermented soy product, HIF = hypercholesterolemic plus isoflavone-
suplemented soy fermented product.
Table 3 Fecal bacterial counts (log cfu/g) in rabbits
during the experimental period
Groups T0 T60 T0 T60
Enterococcus spp. Lactobacillus spp.
C 5.87 ± 0.08
B 6.90 ± 0.01
A 6.51 ± 0.02
B 6.99 ± 0.02
A
H 7.26 ± 0.01
A 6.85 ± 0.01
B 8.07 ± 0.11
A 7.17 ± 0.01
B
HUF 7.23 ± 0.04
B 7.50 ± 0.02
A 8.92 ± 0.04
A 8.11 ± 0.01
B
HF 6.60 ± 0.01
B 7.97 ± 0.02
A 7.28 ± 0.02
B 8.55 ± 0.05
A
HIF 5.27 ± 0.01
B 7.68 ± 0.03
A 7.50 ± 0.03
B 8.16 ± 0.02
A
Bifidobacterium spp. Enterobacteria
C 5.46 ± 0.11
B 6.56 ± 0.01
A 8.81 ± 0.06
A 7.86 ± 0.04
B
H 8.54 ± 0.01
A 6.91 ± 0.03
B 8.16 ± 0.01
A 6.71 ± 0.02
B
HUF 9.04 ± 0.02
A 7.93 ± 0.01
B 8.32 ± 0.03
A 6.96 ± 0.02
B
HF 7.61 ± 0.01
B 8.29 ± 0.02
A 7.00 ± 0.05
A 3.47 ± 0.05
B
HIF 8.59 ± 0.03
A 8.07 ± 0.12
B 7.59 ± 0.23
A 6.64 ± 0.05
B
Clostridium spp.
C 8.77 ± 0.05
A 7.85 ± 0.07
B
H 8.69 ± 0.01
A 7.33 ± 0.01
B
HUF 8.90 ± 0.02
A 7.67 ± 0.01
B
HF 7.41 ± 0.05
A 7.53 ± 0.11
A
HIF 8.69 ± 0.05
A 8.04 ± 0.01
B
Groups: C = control, H = hypercholesterolemic, HUF = hypercholesterolemic
plus unfermented soy product, HF = hypercholesterolemic plus fermented soy
product, HIF = hypercholesterolemic plus isoflavone-supplemented soy
fermented product. T0 = before the start of the study, T60 = end of the
ingestion period. Statistical comparison of times: means with identical upper-
case letters in the same row do not differ significantly (P ≤ 0.05).
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been extensively studied and include: inhibition of breast
and colon cancer [29,30], prevention of osteoporosis,
modulation of the immune system [31] and hypocholes-
terolemic effect [7-10].
The enterobacteria group is represented mainly by
Escherichia coli, Salmonella spp., Shigella spp., Yersinia
enterocolitica, Klebsiella spp., Proteus spp. and Citrobac-
ter spp. and is related to intestinal and extra-intestinal
infections. In this study, all the animals groups showed
reduction in the enterobacteria population, with the
most expressive results being obtained with probiotic
fermented soy product (HF) ingestion. The inhibition of
potentially pathogenic bacteria by a probiotic could be
related to the production of various acids, hydrogen per-
oxide or bacteriocins, the competition for nutrients or
adhesion receptors, anti-toxin action and stimulation of
the immune system [32-34].
We also observed a reduction on Clostridium spp. after
ingestion of unfermented soy product and isoflavone-
supplemented soy product. However, the fermented soy
p r o d u c ta l o n e( H F )d i dn o ta l t e rt h eClostridium spp.
population. In an earlier study, it was found that the
same fermented soy product led to an increase in the
number of viable cells of Clostridium spp. in the feces of
rats fed on a beef-based diet [26]. The possible explana-
tion for this observation was that the E. faecium CRL 183
or the metabolites generated during fermentation pro-
mote the increase in the Clostridium spp. population.
Clostridium spp. is a major component of normal anae-
robic microbiota and some species may cause infectious
diseases in humans [35]. However, in this study the iden-
tification of bacteria to species level was not done and it
is thus not possible to decide whether the rise in the
Clostridium spp. population is prejudicial or not.
Cardiovascular diseases are related to dyslipidemia
(high levels of total cholesterol and low-density lipopro-
tein and low levels of high-density lipopprotein). The
present study showed a strong correlation between
microbiota composition and lipid profile. Population of
Enterococcus spp., Lactobacillus spp. and Bifidobacter-
ium spp. were negatively associated with total choles-
terol, non-HDL-cholesterol, autoantibodies against
oxidized LDL (oxLDL Ab) and lesion size. Clostridium
spp. viable cells in the feces were negatively associated
with antibodies against oxidized LDL (oxLDL Ab) and
lesion size. HDL-C levels were positively associated with
Lactobacillus spp., Bifidobacterium spp. and Enterococ-
cus spp. populations.
Several studies have reported the beneficial effects of
bifidobacteria and lactobacilli on lipid metabolism, when
they are administered as probiotics or when their
growth is stimulated by prebiotics [4,36-38]. Martinez et
al (2009) [4] showed that consumption of grain sorghum
lipid extract (GSL) improved the high-density lipopro-
tein equilibrium (HDL/non-HDL cholesterol) and this
effect was associated with alteration in gut microbiota.
Bifidobacterium spp. population exhibited a strong posi-
tive correlation with plasma cholesterol levels (r = 0.75;
P = 0.001). Wang et al. (2009) [39] showed that inges-
tion of a diet supplemented with lyophilized L. plan-
tarum MA2 (10
11 CFU/day) significantly lowered serum
total cholesterol, low-density lipoprotein cholesterol, and
triglycerides level in mice. The authors also observed an
increase in the Lactobacillus spp. and Bifidobacterium
spp. populations.
In vitro experiments, have demonstrated that E. faecium
CRL183 reduces cholesterol by 53.85% [40] and 51.20%
[41]. We have also reported that the soy product fermen-
ted with E. faecium CRL 183 and Lactobacillus helveticus
416 can improve the lipid parameters in animal and
human tests [7-9].
The mechanism of hypolipemiant action, although not
completely known, involves assimilation of cholesterol,
deconjugation of bile salts and fermentation of non-
digestible carbohydrates from the diet, producing short-
chain fatty acids [42,43].
The first hypothesis suggests that some microorgan-
isms may assimilate cholesterol or incorporate this sub-
stance into the cell membrane, but this is not the
consensus [44]. A second hypothesis considers that
some bacterial species (such as bifidobacteria, lactoba-
cilli, clostridia and streptococci) exhibit bile salt hydro-
lase activity being able to hydrolyze bile acids. Cholic
and deoxycholic acids, bile acids produced from choles-
terol by hepatocytes, are conjugated with glycine and
Table 4 Correlation (r value) between bacterial populations, lipid parameters and lesion size
Bacterial population Total Cholesterol non-HDL-C HDL-C ox-LDL Ab Lesion size
Enterococcus spp. - 0.98 (0.19) -0.98 (0.18) 0.97 (0.66) -0.90 (0.45) -0.84 (0.09)
Lactobacillus spp. - 0.99 (0.37) -0.99 (0.32) 0.95 (0.57) -0.96 (-0.33) -0.78 (0.26)
Bifidobacterium spp. - 0.99 (0.27) -0.99 (0.27) 0.90 (0.57) -0.99 (-0.40) -0.81 (0.19)
Enterobacteria 0.60 (0.27) 0.6022 (-0.27) -0.79 (-0.57) 0.40 (0.07) 0.43 (-0.24)
Clostridium spp. -0.49 (-0.49) -0.49 (-0.50) 0.37 (0.41) -0.76 (0.73) -0.76 (-0.66)
Correlation coefficients with an r superior of 0.7 are shown in bold face type.
Values including control animals are presented in parentheses..
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Page 6 of 9taurine, respectively [45]. Desconjugated bile acids are
not absorbed by the large intestine and are excreted
through the feces and urine. In this situation, more cho-
lesterol is used to synthesize bile acids, leading to a fall
in blood cholesterol levels [37,45,46]. Finally, some bac-
terial species in the large intestine ferment unabsorbed
carbohydrates to produce short-chain fatty acids (SCFA).
Acetate is the major SCFA produced, but the amount of
propionate and butyrate varies. Several studies show that
acetate increases total cholesterol while propionate
reduces the hypercholesterolemic effect caused by acetate
[45,47]. Butyrate is known to inhibit liver cholesterol
synthesis and provide a source of energy for human colon
epithelial cells, while propionate is involved in the inhibi-
tion of the synthesis of fatty acids in the liver, thereby low-
ering the rates of triacylglycerol secretion and the rate of
cholesterol synthesis, which could lead to the improve-
ment of plasma cholesterol levels [48]. The hypolipidemic
effect of probiotic bacteria probably involves production of
sufficient propionate and butyrate to offset the effects of
acetate. An increase in the number of lactic acid bacteria,
such as lactobacilli and bifidobacteria in the gut was corre-
lated with a higher concentration of lactic acid, that may
be converted in acetic and butyric acid [49]. In an in vitro
experiment, Meimandipou et al, (2009) [50] found that
L. agilis JCM 1048 and L. salivarius ssp. salicinius JCM
1230 increased the total anaerobes, lactobacilli and bifido-
bacteria population after 24 h incubation and enhanced
the production of lactate, propionate and butyrate. In the
present work, SCFA were not analyzed and further studies
are necessary to investigate this point. However, we believe
that a beneficial modification of the microbiota composi-
tion, observed on consumption of the fermented soy pro-
duct, with or without isoflavones, could collaborate to
increase of the propionate and butyrate production, so
that cholesterol concentrations may be altered positively.
Oxidative modification of LDL induces the formation
of immunogenic epitopes in the LDL, leading to the gen-
eration of antibodies against oxidized LDL (oxLDL Ab)
[51]. We found that generation of autoantibodies against
ox LDL was highest (P < 0.05) in the hypercholesterole-
mic group (H) and that the intake of soy fermented pro-
ducts (HF and HIF) prevented the rise in this parameter
during the experiment. The reduction in non-HDL-C
concentrations (LDL+VLDL+IDL), with a consequent
reduction in LDL particles available for oxidation,
observed in the HF and HIF groups could, partially,
explain this effect. The importance of oxLDL Ab in
atherogenesis remains unclear.
Infections have been thought to cause or promote
atherosclerosis by increasing pro-atherosclerotic changes
in vascular cells. These changes involve a rise in scaven-
ger receptor expression, enhancement in uptake of
cholesterol and modified low-density lipoprotein and an
increase in the expression of adhesion molecules and
inflammatory cytokines, leading to atherosclerotic plaque
vulnerability [52]. Considering that atherosclerosis is a
chronic immune inflammatory disease, it is possible that
increased populations of Bifidobacterium spp., Lactoba-
cillus spp. and Enterococcus spp., microorganisms that
exhibit immunoregulatory properties, may be linked to
the development of the atherosclerotic lesion [29,53].
Conclusions
The results of this study suggest that daily ingestion of
the probiotic soy product, supplemented or not with iso-
flavones, may contribute to a beneficial balance of the
fecal microbiota. The findings also indicate that the mod-
ulation of microbiota is associated with an improved cho-
lesterol profile and inhibition of atherosclerotic plaque
formation.
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